The U.S. Food and Drug Administration has converted the accelerated approval of Pfizer’s BRAFTOVI (encorafenib) plus cetuximab and fluorouracil-based chemotherapy to full approval for first-line treatment of adult patients with BRAF V600E-mutant metastatic colorectal cancer. This label expansion covers combination with mFOLFOX6 or FOLFIRI regimens, providing oncologists with an approved targeted option beyond standard chemotherapy.

In the randomized, active-controlled BREAKWATER trial, BRAFTOVI plus cetuximab and mFOLFOX6 achieved a 47% reduction in disease progression or death (HR 0.53; 95% CI 0.41–0.68; p<0.0001) and a 51% reduction in mortality (HR 0.49; 95% CI 0.38–0.63; p<0.0001) versus chemotherapy with or without bevacizumab. Median progression-free survival improved to 12.8 months from 7.1 months, while median overall survival doubled to 30.3 months versus 15.1 months in the control arm.

The safety profile of the BRAFTOVI combination remained consistent with known effects of each agent, and no new safety signals emerged. Common adverse events (≥25%) in the mFOLFOX6 arm included peripheral neuropathy, nausea, fatigue and diarrhea, with a 14% treatment discontinuation rate for BRAFTOVI. In the FOLFIRI arm, common events were nausea, diarrhea and fatigue, with 9% discontinuation due to adverse reactions.

Beyond the U.S., the BRAFTOVI combination with mFOLFOX6 is under review in Europe, where Pierre Fabre Laboratories holds commercialization rights, and has already gained approvals in multiple markets. The expanded indication offers flexibility to pair BRAFTOVI with different fluorouracil-based regimens, positioning Pfizer to capture a larger share of the metastatic colorectal cancer segment and reinforce its oncology growth trajectory.